<DOC>
	<DOCNO>NCT02348918</DOCNO>
	<brief_summary>A Phase 2 Randomized , Controlled , Double-Masked , Multicenter Clinical trial Designed Evaluate Safety Exploratory Efficacy Luminate® ( ALG-1001 ) Compared Avastin® Focal Laser Photocoagulation Treatment Diabetic Macular Edema</brief_summary>
	<brief_title>A Phase 2 Randomized , Controlled , Double-Masked , Multicenter Clinical Trial Designed Evaluate Safety Exploratory Efficacy Luminate® ( ALG-1001 ) Compared Avastin® Focal Laser Photocoagulation Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>To evaluate safety efficacy Luminate® ( ALG-1001 ) compare Avastin® focal laser photocoagulation patient diabetic macular edema - 150 eligible subject DME enrol randomize one 5 treatment group , i.e. , one three dos Luminate intravitreal injection Avastin intravitreal injection focal laser photocoagulation . Subjects follow monthly 24 week ( 6 month )</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Male female , 18 year age old . 2 . Study eye clinically significant diabetic macular edema ( DME ) central subfield thickness ≥ 350µm spectral domain OCT 3 . Best correct visual acuity ( BCVA ) 20/50 20/320 ETDRS equivalent ( 65 letter 23 letter ) study eye , BCVA decrement primarily attributable DME . 4 . Treatment naïve , i.e. , previous antiVEGF treatment study eye antiVEGF treatment 45 day prior study enrollment . 5 . In investigator 's opinion , subject still significant intraretinal fluid room improvement macular edema BCVA . 6 . IntraOcular Pressure ( IOP ) control ( i.e. , IOP ≤ 25 mm study eye ) study eye receive IOP lower drop . 7 . Willing able return study visit . 8 . Able meet extensive postop evaluation regimen . 9 . Understands sign inform consent form . 1 . Active proliferative diabetic retinopathy ( PDR ) study eye NVE , NVD , vitreous hemorrhage , neovascular glaucoma . 2 . Uncontrolled hypertension define systolic &gt; 180 mmHg &gt; 160 mmHg 2 consecutive measurement diastolic &gt; 100 mmHg optimal medical regimen 3 . Screening HgA1c blood test &gt; 10.0 4 . Focal laser photocoagulation intravitreal/periocular steroid type study eye within last 90 day prior study enrollment . 5 . A history intravitreal antiVEGF injection type study eye within last 45 day prior study enrollment . 6 . History rhegmatogenous retinal detachment , retinal tear ( ) , traction retinal detachment study eye . 7 . Epiretinal membrane and/or vitreomacular traction study eye determine central reading center . 8 . Previous par plana vitrectomy study eye 9 . Any intraocular surgery study eye within last 90 day prior study enrollment . 10 . YAG laser treatment study eye last 30 day prior study enrollment . 11 . High myopia study eye , spherical equivalent &gt; 8.00D screen 12 . Other ocular pathology investigator 's opinion would interfere subject 's vision study eye . 13 . Chronic recurrent uveitis . 14 . Ongoing ocular infection inflammation either eye . 15 . A history cataract surgery complications/vitreous loss study eye . 16 . Congenital eye malformation study eye . 17 . A history penetrate ocular trauma study eye . 18 . Mentally handicap . 19 . Pregnant female , determine woman less 60 year old positive urine pregnancy test screening window . 20 . Nursing female . 21 . Currently participate clinical research study . 22 . Contraindication study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>